$CPE, $HZNP, $IOVA - On our trading list with news today or analyst comments with our opinion & trade ideas.Callon Petroleum price target raised, Horizon's dip a buying opportunity according to Stifel, and Iovance price target raised.Callon Petroleum price target raised to $20 from $16 at RBC CapitalRBC Capital analyst Brad Heffern raised the firm's price target on Callon Petroleum to $20 from $16 and keeps an Outperform rating on the shares. The analyst is positive on the company's leverage to "strong" oil prices, stating that the stock provides exposure to small cap energy while demonstrating "continued organic improvement" in operational and financial metrics. Heffern adds that Callon management's "self-help strategy" should reduce the company's financial leverage to peer averages over the next 12-18 months.Our Take: Oil prices have been improving. We like this company and stock. Only issue we have with it right now is it already has more than doubled off it's lows in just a month or so. $CPE, Callon Petroleum Company / H1 Horizon Therapeutics share pressure 'a buying opportunity,' says StifelStifel analyst Annabel Samimy reiterates a Buy rating on Horizon Therapeutics, with a price target of $108, and sees share pressure related to the Tepezza supply disruption as "a buying opportunity." Catalent is prioritizing COVID vaccine development, maintaining only one manufacturing slot for Tepezza starting late-December and into Q1, the analyst notes. Samimy understands the restricted capacity will disrupt Q1 2021 sales as current and new patients are warehoused, only to recover in Q2 2021 - hence any impact is primarily related to timing. Given the acute nature of TED and urgency to treat, the analyst largely expects patient return, with new patient starts paused until supply resumes. Ultimately, Horizon Therapeutics should emerge in a stronger manufacturing position to meet peak demand of greater than $3B, Samimy contends.Our Take: Dipping on a short term Covid related issue, nothing actually wrong with the company or any product. Definitely looks like a buying opportunity on dips.Iovance Biotherapeutics price target raised to $55 from $43 at BarclaysBarclays analyst Peter Lawson raised the firm's price target on Iovance Biotherapeutics (IOVA) to $55 from $43 and keeps an Overweight rating on the shares. The recent positive data seen from several cellular therapy companies, including Fate Therapeutics' (FATE) iPSCs, has a positive read-through to cellular therapies including for Iovance's approach with tumor infiltrating lymphocytes, Lawson tells investors in a research note. The analyst now has increased confidence that the FDA approves Iovance's TIL products.Our Take: FDA approval and success chances are quite good for IOVA. This is on our favorites list and a good buy on dips. We also would play this with selling naked puts and selling covered calls.Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .